BioSeek’s BioMAP will be used to advance UCB’s preclinical program.

BioSeek and UCB will jointly evaluate a number of UCB compounds across several target classes in support of target differentiation, lead development, and drug candidate selection using BioSeek’s BioMAP® Systems.

BioMAP Systems are a series of human primary cell-based assays designed to replicate cell and pathway interactions in human disease biology. BioMAP profiling provides characterization of drug function including defining mechanism of action and secondary activities and can provide insights into potential clinical applications, according to BioSeek.

In addition to characterizing previously identified lead compounds, BioSeek is using BioMAP for primary screening to rapidly generate lead compounds that have novel activity in a particular disease setting.

Previous articleResearchers Identify Protein’s Role in Synapse Formation
Next articleBioAlliance to Advance Immtech’s Pafuramidine in Europe for $3M Upfront